- Home
- SNTI vs LAES Comparison
SNTI vs LAES Comparison
Compare SNTI & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- LAES
- Stock Information
- Founded
- SNTI 2016
- LAES 2022
- Country
- SNTI United States
- LAES Switzerland
- Employees
- SNTI N/A
- LAES N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- LAES Semiconductors
- Sector
- SNTI Health Care
- LAES Technology
- Exchange
- SNTI Nasdaq
- LAES Nasdaq
- Market Cap
- SNTI 10.4M
- LAES 10.7M
- IPO Year
- SNTI N/A
- LAES N/A
- Fundamental
- Price
- SNTI $2.15
- LAES $0.38
- Analyst Decision
- SNTI
- LAES Strong Buy
- Analyst Count
- SNTI 0
- LAES 1
- Target Price
- SNTI N/A
- LAES $1.75
- AVG Volume (30 Days)
- SNTI 16.0K
- LAES 890.7K
- Earning Date
- SNTI 11-26-2024
- LAES 09-25-2024
- Dividend Yield
- SNTI N/A
- LAES N/A
- EPS Growth
- SNTI N/A
- LAES N/A
- EPS
- SNTI N/A
- LAES N/A
- Revenue
- SNTI N/A
- LAES $20,135,000.00
- Revenue This Year
- SNTI $254.47
- LAES N/A
- Revenue Next Year
- SNTI $169.66
- LAES N/A
- P/E Ratio
- SNTI N/A
- LAES N/A
- Revenue Growth
- SNTI N/A
- LAES N/A
- 52 Week Low
- SNTI $1.52
- LAES $0.29
- 52 Week High
- SNTI $7.43
- LAES $3.95
- Technical
- Relative Strength Index (RSI)
- SNTI 44.66
- LAES 46.09
- Support Level
- SNTI $2.12
- LAES $0.31
- Resistance Level
- SNTI $2.40
- LAES $0.46
- Average True Range (ATR)
- SNTI 0.16
- LAES 0.05
- MACD
- SNTI 0.02
- LAES 0.01
- Stochastic Oscillator
- SNTI 13.98
- LAES 45.91
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.